^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | NMS-173 (IDH1 inhibitor, IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
Published date:
10/12/2022
Excerpt:
NMS-173 induced stronger and more durable efficacy than ivosidenib in the HCCC-9810 IDH1 mutant cholangiocarcinoma xenograft model and increased the survival of mice bearing the LEXFAM2734 IDH1 mutant PDX AML line, with a better disease control compared to ivosidenib. NMS-173 was very well tolerated upon repeated administration in different species with a wide therapeutic window in non-GLP and GLP tox studies.
